A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR plus ) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

被引：16
|
作者：
Kaufman, P. A.
Ferrero, J. M.
Bourgeois, H.
Kennecke, H.
De Boer, R.
Jacot, W.
McGreivy, J.
Suzuki, S.
Loh, E.
Robertson, J.
机构：
[1] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[2] Clin Victor Hugo, Hugo, Spain
[3] British Columbia Canc Agcy, Vancouver, BC, Canada
[4] Amgen Inc, Thousand Oaks, CA USA
[5] City Hosp Nottingham, Nottingham, England
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-S1-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-4
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    Robertson, John F. R.
    Ferrero, Jean-Marc
    Bourgeois, Hugues
    Kennecke, Hagen
    de Boer, Richard H.
    Jacot, William
    McGreivy, Jesse
    Suzuki, Samuel
    Zhu, Min
    McCaffery, Ian
    Loh, Elwyn
    Gansert, Jennifer L.
    Kaufman, Peter A.
    [J]. LANCET ONCOLOGY, 2013, 14 (03): : 228 - 235
  • [2] Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Jiang, Zefei
    Li, Wei
    Hu, Xichun
    Zhang, Qingyuan
    Sun, Tao
    Cui, Shude
    Wang, Shusen
    Ouyang, Quchang
    Yin, Yongmei
    Geng, Cuizhi
    Tong, Zhongsheng
    Cheng, Ying
    Pan, Yueyin
    Sun, Yuping
    Wang, Hong
    Ouyang, Tao
    Gu, Kangsheng
    Feng, Jifeng
    Wang, Xiaojia
    Wang, Shubin
    Liu, Tianshu
    Gao, Jinghua
    Cristofanilli, Massimo
    Ning, Zhiqiang
    Lu, Xianping
    [J]. LANCET ONCOLOGY, 2019, 20 (06): : 806 - 815
  • [3] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    [J]. LANCET ONCOLOGY, 2017, 18 (07): : 904 - 916
  • [4] Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
    Yardley, Denise A.
    Ismail-Khan, Roohi R.
    Melichar, Bohuslav
    Lichinitser, Mikhail
    Munster, Pamela N.
    Klein, Pamela M.
    Cruickshank, Scott
    Miller, Kathy D.
    Lee, Min J.
    Trepel, Jane B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2128 - +
  • [5] Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial
    Jones, Robert
    Carucci, Margherita
    Casbard, Angela
    Butler, Rachel
    Bale, Catherine
    Alchami, Fouad
    Bezecny, Pavel
    Joffe, Johnathan
    Moon, Sarah
    Twelves, Chris
    Venkitaraman, Ramachandran
    Waters, Simon
    Howell, Sacha
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 : 19 - 19
  • [6] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR plus ) metastatic breast cancer
    Rampurwala, Murtuza
    Wisinski, Kari B.
    Burkard, Mark E.
    Ehsani, Sima
    O'Regan, Ruth M.
    Carmichael, Lakeesha
    Kim, KyungMann
    Kolesar, Jill
    Tevaarwerk, Amye J.
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 87 - 94
  • [7] A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Cristofanilli, M.
    Valero, V.
    Mangalik, A.
    Rabinowitz, I.
    Arena, F. P.
    Kroener, J. F.
    Curcio, E.
    Watkins, C.
    Magill, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
    Chia, Stephen
    Gradishar, William
    Mauriac, Louis
    Bines, Jose
    Amant, Frederic
    Federico, Miriam
    Fein, Luis
    Romieu, Gilles
    Buzdar, Aman
    Robertson, John F. R.
    Brufsky, Adam
    Possinger, Kurt
    Rennie, Pamela
    Sapunar, Francisco
    Lowe, Elizabeth
    Piccart, Martine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1664 - 1670
  • [9] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR plus ) metastatic breast cancer.
    Rampurwala, Murtuza M.
    Burkard, Mark E.
    Wisinski, Karl Braun
    Chimeh, Sima Ehsani
    Zeal, Jamie
    Koehn, Tamara
    Champeny, Tone L.
    Rettig, Joan
    Kim, KyungMann
    Kolesar, Jill
    Tevaarwerk, Amye
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER plus ) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI).
    Yardley, D. A.
    Ismail-Khan, R.
    Klein, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345